OBIO Relative Valuation
OBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OBIO is overvalued; if below, it's undervalued.
Historical Valuation
Orchestra Biomed Holdings Inc (OBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.69. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：4.68
Fair
-2.94
PE
1Y
3Y
5Y
Trailing
Forward
-2.32
EV/EBITDA
Orchestra Biomed Holdings Inc. (OBIO) has a current EV/EBITDA of -2.32. The 5-year average EV/EBITDA is -1.22. The thresholds are as follows: Strongly Undervalued below -5.04, Undervalued between -5.04 and -3.13, Fairly Valued between 0.69 and -3.13, Overvalued between 0.69 and 2.60, and Strongly Overvalued above 2.60. The current Forward EV/EBITDA of -2.32 falls within the Historic Trend Line -Fairly Valued range.
-2.32
EV/EBIT
Orchestra Biomed Holdings Inc. (OBIO) has a current EV/EBIT of -2.32. The 5-year average EV/EBIT is -2.24. The thresholds are as follows: Strongly Undervalued below -7.81, Undervalued between -7.81 and -5.02, Fairly Valued between 0.55 and -5.02, Overvalued between 0.55 and 3.33, and Strongly Overvalued above 3.33. The current Forward EV/EBIT of -2.32 falls within the Historic Trend Line -Fairly Valued range.
78.30
PS
Orchestra Biomed Holdings Inc. (OBIO) has a current PS of 78.30. The 5-year average PS is 55.72. The thresholds are as follows: Strongly Undervalued below -42.28, Undervalued between -42.28 and 6.72, Fairly Valued between 104.72 and 6.72, Overvalued between 104.72 and 153.72, and Strongly Overvalued above 153.72. The current Forward PS of 78.30 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Orchestra Biomed Holdings Inc. (OBIO) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.77. The thresholds are as follows: Strongly Undervalued below -10.19, Undervalued between -10.19 and -6.48, Fairly Valued between 0.94 and -6.48, Overvalued between 0.94 and 4.65, and Strongly Overvalued above 4.65. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Orchestra Biomed Holdings Inc. (OBIO) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.09. The thresholds are as follows: Strongly Undervalued below -5.49, Undervalued between -5.49 and -3.29, Fairly Valued between 1.11 and -3.29, Overvalued between 1.11 and 3.32, and Strongly Overvalued above 3.32. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Orchestra Biomed Holdings Inc (OBIO) has a current Price-to-Book (P/B) ratio of 6.04. Compared to its 3-year average P/B ratio of 31.12 , the current P/B ratio is approximately -80.58% higher. Relative to its 5-year average P/B ratio of 19.14, the current P/B ratio is about -68.44% higher. Orchestra Biomed Holdings Inc (OBIO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -23.92%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -23.92% , the current FCF yield is about -100.00% lower.
6.04
P/B
Median3y
31.12
Median5y
19.14
-22.15
FCF Yield
Median3y
-23.92
Median5y
-23.92
Competitors Valuation Multiple
The average P/S ratio for OBIO's competitors is , providing a benchmark for relative valuation. Orchestra Biomed Holdings Inc Corp (OBIO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -12.77%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OBIO increased by 17.00% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.56K to -2.42K.
The secondary factor is the Revenue Growth, contributed -12.77%to the performance.
Overall, the performance of OBIO in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Orchestra Biomed Holdings Inc (OBIO) currently overvalued or undervalued?
What is Orchestra Biomed Holdings Inc (OBIO) fair value?
How does OBIO's valuation metrics compare to the industry average?
What is the current P/B ratio for Orchestra Biomed Holdings Inc (OBIO) as of Dec 05 2025?
What is the current FCF Yield for Orchestra Biomed Holdings Inc (OBIO) as of Dec 05 2025?
What is the current Forward P/E ratio for Orchestra Biomed Holdings Inc (OBIO) as of Dec 05 2025?